Virtual meeting
Via Zoom
Description
As part of the twice-monthly SUD Care Continuum ECHO® series, Andrea Jakubowski, MD, MS, will describe the clinical rationale and evidence for initiating long-acting injectable buprenorphine without prolonged sublingual stabilization in people who inject opioids, and discuss practical strategies for initiating, administering, and following patients started on injectable buprenorphine. The didactic will be followed by a de-identified patient case presentation from an ECHO® participant and recommendations from the panel of experts and attendees.
The Substance Use Disorder Care Continuum ECHO® (SUD Care Continuum ECHO®) series offers training and support in addiction treatment, with a focus on supporting front line addiction treatment workforce. This includes health providers in Acute Treatment Services (ATS), Crisis Stabilization Services (CSS), Transitional Support Services (TSS), Opioid Treatment Programs (OTP), long-term residential program, sober and recovery homes, primary care, and psychiatry. This free, case-based tele-mentoring program is designed to increase the capacity of health care providers to implement high-quality and evidence-based addiction treatment.
Intended audience
Providers, nurses, social workers, psychologists, peer supports, other clinical staff, and non-clinicians.
Speakers
Andrea Jakubowski, MD, MS
Andrea Jakubowski, MD, MS is a general internist, addiction medicine specialist, and Assistant Professor of Medicine at Montefiore Medical Center/Albert Einstein College of Medicine. Dr. Jakubowski provides primary care and medications for opioid use disorder in a syringe services program and opioid treatment program, and cares for patients on a hospital addiction consult service. Dr. Jakubowski’s research focuses on expanding access to evidence-based treatments for opioid use disorder within and outside traditional healthcare settings. She currently has a NIDA-funded K23 to study implementation of long-acting injectable buprenorphine in primary care and SSP clinics. The C-DIAS Fellowship has provided Dr. Jakubowski with valuable training in the application of IS theories and frameworks and implementation strategy development and tracking, which she is applying in her K23 project. As a part of the C-DIAS Fellowship, she has also had the opportunity to join Dr. Sara Becker’s research group to conduct a study using the IFASIS (Inventory of Factors Affecting Successful Implementation and Sustainment), a novel C-DIAS measure, to examine determinants of implementing a digital contingency management platform in opioid treatment programs.
Objectives
Following this training, participants will have the knowledge to:
- Describe the clinical rationale and evidence for initiating long-acting injectable buprenorphine without prolonged sublingual stabilization in people who inject opioids.
- Apply practical strategies for initiating, administering, and following patients started on injectable buprenorphine.
Sponsored by
Massachusetts Department of Public Health, Bureau of Substance Addiction Services (DPH/BSAS).
Funding for out of state attendees is provided by the Opioid Response Network (ORN).
Funding for this initiative was made possible (in part) by grant no. 1H79TI085588-02 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
Accreditation information
Please read the Accreditation Information section of the training page to learn about the requirements for receiving credit or a certificate of completion.
